BBLG

MKT CAP:$2M

Bone Biologics Corporation

Market Cap

$2M

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Healthcare·Medical - Devices·🇺🇸·NASDAQ

Stock Price

$1.38-$0.16 (-10.39%)

Apr 21, 2026

Company Details

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein tha...

CEO

Jeffrey Frelick

IPO Date

Oct 13, 2021

Website

www.bonebiologics.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$3M

EPS (Diluted)

-$2.65

Free Cash Flow

-$3M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 11, 2026

PENDING

FY 2025

Mar 2, 2026

$0EPS -$2.65

Q4 2025

Mar 2, 2026

$0EPS -$0.63

Q3 2025

Nov 14, 2025

$0EPS -$0.37

Q2 2025

Aug 14, 2025

$0EPS -$1.33

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$689.5K
Q2 22	$0	$0	-$469.3K
Q3 22	$0	$0	-$1M
Q4 22	$0	$0	-$1M
Q1 23	$0	$0	-$3M
Q2 23	$0	$0	-$3M
Q3 23	$0	$0	-$2M
Q4 23	$0	$0	-$1M
Q1 24	$0	$0	-$903.5K
Q2 24	$0	$0	-$809.7K
Q3 24	$0	$0	-$951.0K
Q4 24	$0	$0	-$2M
Q1 25	$0	$0	-$1M
Q2 25	$0	$0	-$748.1K
Q3 25	$0	$0	-$715.3K
Q4 25	$0	$0	-$733.1K

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$860.8K	-$860.8K
Q2 22	-$360.1K	-$360.1K
Q3 22	-$395.3K	-$395.3K
Q4 22	-$2M	-$2M
Q1 23	-$1M	-$1M
Q2 23	-$4M	-$4M
Q3 23	-$3M	-$3M
Q4 23	-$2M	-$2M
Q1 24	-$1M	-$1M
Q2 24	-$895.9K	-$895.9K
Q3 24	-$572.2K	-$572.2K
Q4 24	-$1M	-$1M
Q1 25	-$926.1K	-$926.1K
Q2 25	-$458.9K	-$458.9K
Q3 25	-$591.4K	-$591.4K
Q4 25	-$714.8K	-$714.8K

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$0
Q3 22	$0
Q4 22	$1
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$5
Q2 25	$5
Q3 25	$0
Q4 25	$5

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+281.1%
Q2 22	—	+102.4%
Q3 22	—	+430.5%
Q4 22	—	+180.8%
Q1 23	—	+356.6%
Q2 23	—	+547.8%
Q3 23	—	+70.7%
Q4 23	—	-10.0%
Q1 24	—	-71.3%
Q2 24	—	-73.4%
Q3 24	—	-54.3%
Q4 24	—	+34.0%
Q1 25	—	+14.9%
Q2 25	—	-7.6%
Q3 25	—	-24.8%
Q4 25	—	-52.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$152.8K	—
Q2 22	$18.7K	—
Q3 22	$32.5K	—
Q4 22	$62.5K	—
Q1 23	$44.8K	—
Q2 23	$16.7K	—
Q3 23	$20.0K	—
Q4 23	$71.1K	—
Q1 24	$52.7K	—
Q2 24	$17.4K	—
Q3 24	$17.9K	—
Q4 24	$100.8K	—
Q1 25	$50.6K	—
Q2 25	$72.9K	—
Q3 25	$0	—
Q4 25	$45.7K	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$36.4K	—	$653.1K
Q2 22	$17.6K	—	$451.7K
Q3 22	$769.4K	$449.9K	—
Q4 22	$755.9K	—	$532.8K
Q1 23	$3M	$556.9K	—
Q2 23	$2M	$744.6K	—
Q3 23	$2M	$506.0K	—
Q4 23	$447.1K	$712.9K	—
Q1 24	$245.6K	—	$657.9K
Q2 24	$350.4K	—	$459.2K
Q3 24	$429.7K	—	$521.3K
Q4 24	$1M	—	$450.4K
Q1 25	$423.6K	—	$614.9K
Q2 25	$191.6K	$556.5K	—
Q3 25	$187.8K	$527.5K	—
Q4 25	$257.2K	$475.9K	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$6M	$0	$6M
Q2 22	$5M	$0	$5M
Q3 22	$5M	$0	$5M
Q4 22	$8M	$0	$8M
Q1 23	$6M	$0	$6M
Q2 23	$7M	$0	$7M
Q3 23	$4M	$0	$4M
Q4 23	$3M	$0	$3M
Q1 24	$3M	$0	$3M
Q2 24	$2M	$0	$2M
Q3 24	$4M	$0	$4M
Q4 24	$3M	$0	$3M
Q1 25	$3M	$0	$3M
Q2 25	$7M	$0	$7M
Q3 25	$6M	$0	$6M
Q4 25	$5M	$0	$5M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	43K	0.0%	+255.5%
Q2 22	43K	0.0%	-15.7%
Q3 22	43K	+0.1%	-15.5%
Q4 22	61K	+41.4%	+41.6%
Q1 23	67K	+10.1%	+55.8%
Q2 23	339K	+404.8%	+686.8%
Q3 23	392K	+15.5%	+807.3%
Q4 23	459K	+17.1%	+651.6%
Q1 24	661K	+44.0%	+883.4%
Q2 24	1M	+76.7%	+244.2%
Q3 24	2M	+50.1%	+347.4%
Q4 24	3M	+68.5%	+543.6%
Q1 25	3M	+7.8%	+381.6%
Q2 25	558K	-82.5%	-52.2%
Q3 25	2M	+221.8%	+2.4%
Q4 25	1M	-34.6%	-60.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	2
Q2 22	$0	2
Q3 22	$0	2
Q4 22	$0	2
Q1 23	$0	2
Q2 23	$0	2
Q3 23	$0	2
Q4 23	$0	2
Q1 24	$0	2
Q2 24	$0	2
Q3 24	$0	2
Q4 24	$0	2
Q1 25	$0	2
Q2 25	$0	2
Q3 25	$0	2
Q4 25	$0	2

Revenue / Employee